Arbutus Biopharma Corp Asset Resilience Ratio
Arbutus Biopharma Corp asset resilience ratio. Arbutus Biopharma Corp (ABUS) has an Asset Resilience Ratio of 26.81% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Arbutus Biopharma Corp (ABUS) liquidity interval to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Arbutus Biopharma Corp (1998–2025)
Asset resilience ratio of Arbutus Biopharma Corp from 1998 to 2025. This chart shows how Arbutus Biopharma Corp's Asset Resilience Ratio has changed over time. Read how much debt does Arbutus Biopharma Corp carry for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Arbutus Biopharma Corp's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Arbutus Biopharma Corp (ABUS) total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $73.45 Million | 26.81% |
| Total Liquid Assets | $73.45 Million | 26.81% |
Asset Resilience Insights
- Very High Liquidity: Arbutus Biopharma Corp maintains exceptional liquid asset reserves at 26.81% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Arbutus Biopharma Corp Industry Peers by Asset Resilience Ratio
Compare Arbutus Biopharma Corp's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Shanghai Medicilon Inc
SHG:688202 |
Biotechnology | 6.69% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767 |
Biotechnology | 0.56% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 79.76% |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880 |
Biotechnology | 5.52% |
Arbutus Biopharma Corp Asset Resilience Ratio by Year (1998–2025)
Arbutus Biopharma Corp asset resilience ratio by year from 1998 to 2025. The table below shows the annual Asset Resilience Ratio data for Arbutus Biopharma Corp.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 77.64% | $73.46 Million | $94.62 Million | +12.12pp |
| 2024-12-31 | 65.52% | $86.29 Million | $131.71 Million | -3.54pp |
| 2023-12-31 | 69.06% | $99.72 Million | $144.40 Million | +9.63pp |
| 2022-12-31 | 59.43% | $116.14 Million | $195.42 Million | +36.92pp |
| 2021-12-31 | 22.51% | $46.03 Million | $204.49 Million | -29.29pp |
| 2020-12-31 | 51.81% | $71.02 Million | $137.08 Million | -4.13pp |
| 2019-12-31 | 55.94% | $59.03 Million | $105.53 Million | +17.47pp |
| 2018-12-31 | 38.47% | $87.67 Million | $227.91 Million | +8.07pp |
| 2017-12-31 | 30.40% | $72.10 Million | $237.20 Million | -8.42pp |
| 2016-12-31 | 38.82% | $107.10 Million | $275.90 Million | +36.78pp |
| 2015-12-31 | 2.04% | $14.53 Million | $712.29 Million | -31.80pp |
| 2014-12-31 | 33.84% | $40.00 Million | $118.20 Million | -- |
| 2013-12-31 | 0.00% | $0.00 | $71.72 Million | -- |
| 2012-12-31 | 0.00% | $0.00 | $52.60 Million | -- |
| 2011-12-31 | 0.00% | $0.00 | $13.70 Million | -- |
| 2010-12-31 | 0.00% | $0.00 | $21.02 Million | -- |
| 2009-12-31 | 0.00% | $0.00 | $41.95 Million | -- |
| 2008-12-31 | 11.12% | $4.71 Million | $42.34 Million | -- |
| 2007-12-31 | 0.00% | $0.00 | $24.83 Million | -- |
| 2006-12-31 | 0.00% | $0.00 | $6.03 Million | -- |
| 2005-12-31 | 0.00% | $0.00 | $18.50 Million | -- |
| 2004-12-31 | 0.00% | $0.00 | $41.10 Million | -- |
| 2003-12-31 | 7.19% | $3.65 Million | $50.73 Million | -26.00pp |
| 2002-12-31 | 33.20% | $17.67 Million | $53.22 Million | +0.76pp |
| 2001-12-31 | 32.44% | $21.93 Million | $67.60 Million | -34.98pp |
| 2000-12-31 | 67.41% | $21.93 Million | $32.52 Million | +37.18pp |
| 1999-12-31 | 30.24% | $8.71 Million | $28.80 Million | -5.51pp |
| 1998-12-31 | 35.75% | $5.66 Million | $15.83 Million | -- |
About Arbutus Biopharma Corp
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and A… Read more